valproic acid has been researched along with Fetal Death in 15 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Fetal Death: Death of the developing young in utero. BIRTH of a dead FETUS is STILLBIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid, a drug commonly used to treat seizures and other psychiatric disorders, causes neural tube defects (NTDs) in exposed fetuses at a rate 20 times higher than in the general population." | 3.73 | Valproic acid-induced fetal malformations are reduced by maternal immune stimulation with granulocyte-macrophage colony-stimulating factor or interferon-gamma. ( Holladay, SD; Hrubec, TC; Salafia, CM; Yan, M; Ye, K, 2006) |
| "The anticonvulsant drug valproic acid (VPA) is suspected to be a developmental toxicant in humans, inducing primarily neural tube defects." | 3.68 | Lack of attenuation of valproic acid-induced effects by folinic acid in rat embryos in vitro. ( Grafton, TF; Hansen, DK, 1991) |
| "Significant decreases in pregnancy weight gain and the number of live fetuses were observed when VPA was administered at the high dose, whereas the percentage of exencephalic fetuses was significantly increased in VPA treated compared with an equivalent VCD dosage group." | 1.51 | Teratogenicity of valproic acid and its constitutional isomer, amide derivative valnoctamide in mice. ( Bialer, M; Cabrera, RM; Finnell, RH; Lin, YL; Wlodarczyk, BJ, 2019) |
| "The influence of dosing time on embryotoxicity of valproate was investigated in ICR (Institute of Cancer Research, USA) mice under light-dark (12:12) cycle." | 1.29 | Circadian rhythm of embryotoxicity induced by sodium valproate in mice. ( Ogawa, N; Ohdo, S; Sugiyama, T; Watanabe, H; Yoshiyama, Y, 1995) |
| " The VPA-400 dose was maternally toxic in as much as maternal weight gain was reduced, but no deaths occurred." | 1.27 | Teratogenicity and developmental toxicity of valproic acid in rats. ( Vorhees, CV, 1987) |
| " The plasma elimination half-life on GD 8 was 1." | 1.27 | Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats. ( Binkerd, PE; Hendrickx, AG; Nau, H; Rowland, JM, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 6 (40.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, YL | 1 |
| Bialer, M | 3 |
| Cabrera, RM | 1 |
| Finnell, RH | 2 |
| Wlodarczyk, BJ | 1 |
| Okada, A | 1 |
| Noyori, H | 1 |
| Yagen, B | 2 |
| Shimshoni, JA | 1 |
| Fujiwara, M | 1 |
| Costa-Borges, N | 1 |
| Gonzalez, S | 1 |
| Santaló, J | 1 |
| Ibáñez, E | 1 |
| Meador, KJ | 1 |
| Baker, GA | 1 |
| Kalayjian, LA | 1 |
| Liporace, JD | 1 |
| Loring, DW | 1 |
| Mawer, G | 1 |
| Pennell, PB | 1 |
| Smith, JC | 1 |
| Wolff, MC | 1 |
| Hrubec, TC | 1 |
| Yan, M | 1 |
| Ye, K | 1 |
| Salafia, CM | 1 |
| Holladay, SD | 1 |
| Sonoda, T | 1 |
| Ohdo, S | 2 |
| Ohba, K | 1 |
| Okishima, T | 1 |
| Hayakawa, K | 1 |
| Watanabe, H | 1 |
| Ogawa, N | 1 |
| Yoshiyama, Y | 1 |
| Sugiyama, T | 1 |
| Hall, JL | 1 |
| Harris, MJ | 1 |
| Juriloff, DM | 1 |
| Radatz, M | 1 |
| Ehlers, K | 1 |
| Nau, H | 3 |
| Fairgrieve, SD | 1 |
| Jackson, M | 1 |
| Jonas, P | 1 |
| Walshaw, D | 1 |
| White, K | 1 |
| Montgomery, TL | 1 |
| Burn, J | 1 |
| Lynch, SA | 1 |
| Hansen, DK | 1 |
| Grafton, TF | 1 |
| Collins, MD | 1 |
| Fradkin, R | 1 |
| Scott, WJ | 1 |
| Hauck, RS | 1 |
| Vorhees, CV | 1 |
| Binkerd, PE | 1 |
| Rowland, JM | 1 |
| Hendrickx, AG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neurodevelopmental Effects of Antiepileptic Drugs II: the NEAD Study[NCT00021866] | 331 participants (Actual) | Observational | 2000-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for valproic acid and Fetal Death
| Article | Year |
|---|---|
In utero antiepileptic drug exposure: fetal death and malformations.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Cognition; Female; Fetal Death; | 2006 |
14 other studies available for valproic acid and Fetal Death
| Article | Year |
|---|---|
Teratogenicity of valproic acid and its constitutional isomer, amide derivative valnoctamide in mice.
Topics: Abnormalities, Drug-Induced; Amides; Animals; Anticonvulsants; Female; Fetal Death; Fetus; Mice; Neu | 2019 |
Anticonvulsant profile and teratogenic evaluation of potent new analogues of a valproic acid urea derivative in NMRI mice.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Bone and Bones; Deep Sedation; Differential T | 2009 |
Effect of the enucleation procedure on the reprogramming potential and developmental capacity of mouse cloned embryos treated with valproic acid.
Topics: Acetylation; Analysis of Variance; Animals; Birth Weight; Blastocyst; Cell Line; Cellular Reprogramm | 2011 |
Valproic acid-induced fetal malformations are reduced by maternal immune stimulation with granulocyte-macrophage colony-stimulating factor or interferon-gamma.
Topics: Abnormalities, Drug-Induced; Adjuvants, Immunologic; Animals; Anticonvulsants; Dose-Response Relatio | 2006 |
Sodium valproate-induced cardiovascular abnormalities in the Jcl:ICR mouse fetus: peak sensitivity of gestational day and dose-dependent effect.
Topics: Animals; Dose-Response Relationship, Drug; Female; Fetal Death; Fetal Resorption; Fetus; Heart Defec | 1993 |
Circadian rhythm of embryotoxicity induced by sodium valproate in mice.
Topics: Animals; Anticonvulsants; Chronobiology Phenomena; Circadian Rhythm; Drug Administration Schedule; E | 1995 |
Effect of multifactorial genetic liability to exencephaly on the teratogenic effect of valproic acid in mice.
Topics: Abnormalities, Drug-Induced; Animals; Brain; Disease Susceptibility; Female; Fetal Death; Mice; Mice | 1997 |
Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid.
Topics: Abnormalities, Drug-Induced; Amides; Animals; Anticonvulsants; Body Weight; Embryo, Mammalian; Femal | 1998 |
Population based, prospective study of the care of women with epilepsy in pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Fetal Death; Guidelin | 2000 |
Lack of attenuation of valproic acid-induced effects by folinic acid in rat embryos in vitro.
Topics: Animals; Dose-Response Relationship, Drug; Embryo, Mammalian; Female; Fetal Death; In Vitro Techniqu | 1991 |
Induction of postaxial forelimb ectrodactyly with anticonvulsant agents in A/J mice.
Topics: Abnormalities, Drug-Induced; Animals; Birth Weight; Dimethadione; Female; Fetal Death; Fetal Resorpt | 1990 |
[Structural bases of the teratogenic effects of the antiepileptic valproic acid. 2-n-propyl-4-pentenic acid, the first structural analogue with significantly higher teratogenic action than VPA].
Topics: Animals; Dose-Response Relationship, Drug; Female; Fetal Death; Fetus; Mice; Organ Size; Pregnancy; | 1989 |
Teratogenicity and developmental toxicity of valproic acid in rats.
Topics: Abnormalities, Drug-Induced; Animals; Animals, Newborn; Body Weight; Dose-Response Relationship, Dru | 1987 |
Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats.
Topics: Administration, Oral; Animals; Body Weight; Female; Fetal Death; Male; Pregnancy; Rats; Rats, Inbred | 1988 |